Havrix Junior Monodose (Hepatitis A Virus (Inactivated), Aluminium Hydroxide)

Havrix Junior Monodose is indicated for specific preventive purposes related to hepatitis A.

• Primary prophylaxis of hepatitis A in children according to national immunization schedules.
• Pre‑exposure vaccination for travelers visiting regions with intermediate or high hepatitis A endemicity.
• Use in outbreak settings to quickly immunize susceptible pediatric populations.
• Administration as part of a two‑dose series, with the second dose typically given 6–12 months after the first.

The safety profile of Havrix Junior Monodose reflects the typical reactions observed with inactivated viral vaccines.

Common

• Mild pain, redness or swelling at the injection site.
• Low‑grade fever.
• Headache.
• Fatigue or general malaise.
• Nausea.

Serious

• Severe allergic reaction (anaphylaxis) characterized by difficulty breathing, swelling of the face or throat, and rapid pulse.
• Guillain‑Barré syndrome, a rare neurological condition.
• Persistent high fever lasting more than 48 hours.
• Seizures (rare).
• Thrombocytopenia (low platelet count).

Healthcare providers should consider several precautionary measures before administering Havrix Junior Monodose.

• Confirm no history of severe allergic reaction to any component of the vaccine, especially aluminium salts.
• Defer vaccination in individuals with acute moderate or severe illness until recovery.
• Use with caution in persons with known immunodeficiency, as response may be reduced.
• Discuss potential benefits versus risks in pregnant or breastfeeding women, as safety data are limited.
• Observe the patient for at least 15 minutes after injection to monitor for immediate reactions.
• Record any previous hepatitis A vaccination to avoid unnecessary repeat dosing.

Havrix Junior Monodose may interact with other agents, influencing its efficacy or safety.

Avoid

• Simultaneous administration with live viral vaccines (e.g., measles, mumps, rubella) unless separated by at least 4 weeks.
• Use with immunoglobulin products that contain hepatitis A antibodies, which can neutralize the vaccine antigen.

Use with caution

• Concomitant administration of other inactivated vaccines (e.g., diphtheria‑tetanus‑pertussis) may increase local reactogenicity.
• Patients receiving immunosuppressive therapy may have a diminished antibody response.
• Antipyretics taken prophylactically may mask mild fever after vaccination.